Highest-materiality recent filing
All seven director nominees elected; votes for ranged from 28.5M (Cucuz) to 34.5M (Reuvers); broker non-votes 14.66M.
Francis X. Brown III continues as Interim Principal Financial and Accounting Officer under amended agreement dated May 18, 2026.
Neuronetics Q1 revenue $34.5M (+8% YoY); net loss improves; maintains FY2026 outlook
Revenue $34.5M (+8% YoY); U.S. clinic revenue $21.5M (+15%) on Greenbrook acquisition and SPRAVATO expansion.
Neuronetics announces CFO resignation, 5% workforce reduction, and former CEO consulting deal
Former CEO Keith J. Sullivan enters consulting agreement with release; will vest in equity through March 2027; no additional compensation.
Neuronetics appoints new CEO Dan Reuvers; Q4 revenue $41.8M, net loss $7.2M; FY26 guidance $160-166M
Dan Reuvers appointed President and CEO effective March 23, 2026; base salary $730k, 1.5M RSU grant.
Second Amendment to Registration Rights Agreement executed March 2, 2026.
Neuronetics approves $649K in annual cash incentives for CEO, CFO, and CLO
CEO Keith J. Sullivan receives $412,775.95 annual cash incentive award.
Q4 revenue $41.8M, 23% YoY pro forma growth; NeuroStar revenue $18.3M (+9% pro forma).
Amendment introduces 'Immaterial Subsidiary' definition: assets/revenue ≤ $5M each, aggregate ≤ $10M.
Neuronetics grants $240K cash + 170K RSUs to CFO, $231.75K cash + 164K RSUs to GC
Cash award of $240,000 and 170,212 RSUs granted to CFO Steven E. Pfanstiel.
Revenue $37.3M (+101% YoY, +11% adjusted pro forma); Greenbrook clinic revenue $21.8M (+25% adj pro forma).
Q2 2025 revenue $38.1M, up 132% YoY; adjusted pro forma growth 18%; net loss $(9.8)M ($0.15 loss per share).
Neuronetics appoints Steven Pfanstiel as CFO; reaffirms Q2 & FY2025 guidance
Pfanstiel named CFO effective July 15, replacing retiring Steve Furlong (through March 2026).
Neuronetics shareholders reject supermajority elimination; all directors elected
All 7 director nominees elected with >36.7M votes each; broker non-votes of ~15.8M.
Neuronetics Q1 revenue $32M (+84% YoY); narrows FY guidance; CFO to retire March 2026
Q1 revenue $32.0M, up 84% YoY driven by Greenbrook acquisition; net loss $(12.7)M vs $(7.9)M
Q4 2024 net loss revised to $(12.7)M ($(0.34)/share) from $(12.2)M ($(0.33)/share) initially reported.
Neuronetics approves 2025 annual cash incentive awards for CEO, CFO, and GC
CEO Keith J. Sullivan receives $169,260 annual cash incentive award approved by Board on Feb 24.
Neuronetics Q4 rev $22.5M (+11% YoY); closes Greenbrook TMS, guides FY25 rev $145-155M
Q4 2024 total revenue $22.5M (+11% YoY); U.S. treatment session revenue $12.9M; clinic revenue from Greenbrook $4.4M.
Neuronetics prices $18M public offering of 8M shares at $2.25/share
Gross proceeds ~$18M from 8M shares (plus underwriter option 1.2M shares exercised).
Neuronetics files Greenbrook FY22-23 audited, Q3 2024 unaudited, and pro forma financials
Acquisition of all Greenbrook common shares closed December 9, 2024.
Preliminary Q4 2024 revenue $22.1M; full-year 2024 revenue $74.5M (combined with Greenbrook from Dec 9).
Neuronetics closes Greenbrook TMS acquisition; adds 2 directors; secures $10M loan amendment.
Acquisition closed Dec 9; exchange ratio 0.01021 Neuronetics share per Greenbrook share; Greenbrook to delist from OTCQB.
Neuronetics Q3 rev $18.5M (+4% YoY); cash flow breakeven shifted to Q3 2025
Q3 revenue $18.5M (+4% vs Q3 2023); U.S. system revenue $4.1M (+14%), treatment session revenue $13.3M (+2%).
Neuronetics regains Nasdaq minimum bid price compliance; delisting risk resolved
Nasdaq notified Neuronetics on Nov 12 that it regained compliance with the $1.00 minimum bid price rule.
Revenue $18.5M (+4% YoY); U.S. system revenue $4.1M (+14%) on 48 units; treatment session revenue $13.3M (+2%)
Neuronetics reduces workforce by 10%, expects >$3.5M annual cash savings
Workforce reduction of approximately 10% to sharpen focus on growth.
Neuronetics shareholders approve all proposals for Greenbrook acquisition
Charter amendment to increase authorized shares to 250M approved with 16.66M for, 7.33M against.
Neuronetics extends Madryn's demand registration period from 180 to 365 days post-merger close
Amends Registration Rights Agreement with Madryn Asset Management LP.
Ontario court grants interim order for statutory plan of arrangement; Neuronetics to acquire Greenbrook in all-stock transaction.
Neuronetics gets Nasdaq deficiency notice for bid price below $1.00; 180-day cure period
Received Nasdaq letter on Oct 3, 2024; stock closed below $1.00 for 30 consecutive business days.
Neuronetics files investor presentation highlighting benefits of Greenbrook acquisition
Presentation distributed on Oct 2, 2024 detailing strategic rationale and financial benefits of buying Greenbrook TMS Inc.
Neuronetics hosts fireside chat on proposed acquisition of Greenbrook TMS
Neuronetics CEO Keith Sullivan and Greenbrook CEO Bill Leonard discuss deal impact on NeuroStar practices.
Neuronetics announces FDA clearance for NeuroStar add-on therapy for ages 15 and older
FDA cleared NeuroStar Advanced Therapy System as an add-on treatment for patients aged 15 and older.
Neuronetics issues ~25.3M shares to Greenbrook holders; existing Neuronetics shareholders own 57% of combined entity.
Neuronetics to acquire Greenbrook TMS in all-stock deal; Q2 revenue down 7%, net loss widens
Q2 revenue $16.5M (-7% YoY); net loss $(9.8)M ($0.33) vs $(4.9)M ($0.17) prior year.
Neuronetics reports Q2 2024 financial results and proposed combination with Greenbrook TMS
Neuronetics issued a press release on August 12, 2024, announcing unaudited financial results for the three and six months ended June 30, 2024.
Neuronetics enters up to $90M credit facility with Perceptive, replaces SLR debt
Borrowed $50M initial tranche, used $64.6M to repay SLR Investment Corp. loan in full including fees and interest.
Neuronetics presents financial and operational outlook at William Blair conference
Presentation provides FY2024 outlook metrics but specific numbers not extracted.
Neuronetics annual meeting results: all director nominees elected, advisory votes pass
All five director nominees elected; For votes ranged from 15.3M to 17.7M; broker non-votes of 5.4M.
Neuronetics posts May 2024 investor presentation to website; no specific financials provided
Filed under Item 7.01 Regulation FD Disclosure on May 7, 2024.
Neuronetics Q1 revenue $17.4M (+12% YoY); FDA clearance for adolescent MDD expands TAM by ~35%
Revenue $17.4M (+12% YoY); U.S. treatment session revenue $13.0M (+22% YoY) driven by higher utilization.
Neuronetics reduces board to five directors; three incumbents depart
Board size cut from 8 to 5 effective after 2024 annual meeting.
Neuronetics gets FDA clearance for NeuroStar as first-line adjunct for adolescent MDD (ages 15-21)
FDA cleared NeuroStar Advanced Therapy as first-line adjunct treatment for major depressive disorder in adolescents aged 15-21.
Neuronetics approves annual cash incentive awards: CEO $660,800, two EVPs $226,341 and $206,747
CEO Keith J. Sullivan receives $660,800 annual cash incentive award, approved by Board on March 1, 2024.
Neuronetics posts investor presentation; filing contains no specific financial updates
Investor presentation and supplemental financial/operating info posted to ir.neuronetics.com.
Neuronetics Q4 revenue up 12% to $20.3M; net loss narrows to $5.4M; first positive cash flow
Q4 2023 revenue $20.3M (+12% YoY); full-year revenue $71.3M (+9% YoY).
On May 6, 2025, the Company announced that Stephen Furlong, who has served as Chief Financial Officer since 2019, will retire on March 31, 2026.
Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.
Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.
Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.
Max materiality 0.90 · Median 0.65 · Most common event earnings